ReviewMicrobial biotechnology2011
Molecular insights on the biosynthesis of antitumour compounds by actinomycetes.
Review in Microbial biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Uncovering antioxidant and anti-breast cancer potential metabolite fromFrontiers in pharmacology · 2026Article
- An Overview of Lsr2 Repressor Effect inMicroorganisms · 2024Article
- Genome Mining for Diazo-Synthesis-Related Genes inBiomolecules · 2024Article
- Volatile communication in Actinobacteria: a language for secondary metabolism regulation.Microbial cell factories · 2024Article
- Colibrimycins, Novel Halogenated Hybrid Polyketide Synthase-Nonribosomal Peptide Synthetase (PKS-NRPS) Compounds Produced byApplied and environmental microbiology · 2022Article
- Streptomycetes as platform for biotechnological production processes of drugs.Applied microbiology and biotechnology · 2021Review
- Genome Mining as New Challenge in Natural Products Discovery.Marine drugs · 2020Review
- New Sipanmycin Analogues Generated by Combinatorial Biosynthesis and Mutasynthesis Approaches Relying on the Substrate Flexibility of Key Enzymes in the Biosynthetic Pathway.Applied and environmental microbiology · 2020Article
- Searching for Glycosylated Natural Products in Actinomycetes and Identification of Novel Macrolactams and Angucyclines.Frontiers in microbiology · 2018Article
- Novel Bioactive Paulomycin Derivatives Produced by Streptomyces albus J1074.Molecules (Basel, Switzerland) · 2017Article
- Exploring the biocombinatorial potential of benzoxazoles: generation of novel caboxamycin derivatives.Microbial cell factories · 2017Article
- Engineering microbial hosts for production of bacterial natural products.Natural product reports · 2016Review
- Natural product discovery: past, present, and future.Journal of industrial microbiology & biotechnology · 2016Review
- Recent advances in combinatorial biosynthesis for drug discovery.Drug design, development and therapy · 2015Review
- Biochemical and structural characterization of germicidin synthase: analysis of a type III polyketide synthase that employs acyl-ACP as a starter unit donor.Journal of the American Chemical Society · 2012Article
- Streptomycetes.Microbial biotechnology · 2011Article
- Streptomyces globosus DK15 and Streptomyces ederensis ST13 as new producers of factumycin and tetrangomycin antibiotics.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural products are traditionally the main source of drug leads. In particular, many antitumour compounds are either natural products or derived from them. However, the search for novel antitumour drugs active against untreatable tumours, with fewer side-effects or with enhanced therapeutic efficiency, is a priority goal in cancer chemotherapy. Microorganisms, particularly actinomycetes, are prolific producers of bioactive compounds, including antitumour drugs, produced as secondary metabolites. Structural genes involved in the biosynthesis of such compounds are normally clustered together with resistance and regulatory genes, which facilitates the isolation of the gene cluster. The characterization of these clusters has represented, during the last 25 years, a great source of genes for the generation of novel derivatives by using combinatorial biosynthesis approaches: gene inactivation, gene expression, heterologous expression of the clusters or mutasynthesis. In addition, these techniques have been also applied to improve the production yields of natural and novel antitumour compounds. In this review we focus on some representative antitumour compounds produced by actinomycetes covering the genetic approaches used to isolate and validate their biosynthesis gene clusters, which finally led to generating novel derivatives and to improving the production yields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.